



Clinical trial results:

A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixustat Hydrochloride with Placebo for the Treatment of Macular Atrophy Secondary to Stargardt Disease

Summary

EudraCT number	2018-003498-82
Trial protocol	GB FR DK DE ES NL IT
Global end of trial date	23 June 2022

Results information

Result version number	v1 (current)
This version publication date	05 July 2023
First version publication date	05 July 2023

Trial information

Trial identification

Sponsor protocol code	4429-301
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03772665
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Acucela dba Kubota Vision
Sponsor organisation address	600 University Street, Seattle, United States, 98101
Public contact	Clinical Trial Helpdesk, Acucela , +1 2068058310, ClinicalTrials@acucela.com
Scientific contact	Clinical Trial Helpdesk, Acucela , +1 2068058310, ClinicalTrials@acucela.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	23 June 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	23 June 2022
Global end of trial reached?	Yes
Global end of trial date	23 June 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To determine if emixustat hydrochloride (emixustat) reduces the rate of progression of macular atrophy (MA) compared to placebo in subjects with Stargardt disease (STGD)

Protection of trial subjects:

The study was conducted in accordance with the Declaration of Helsinki and its most recent update, and the International Council for Harmonisation (ICH) E6 Good Clinical Practice (GCP) guideline. The study was also conducted in accordance with local legal and regulatory requirements of the countries involved, and with standard operating procedures in place.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	07 November 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 5
Country: Number of subjects enrolled	Spain: 7
Country: Number of subjects enrolled	United Kingdom: 9
Country: Number of subjects enrolled	Denmark: 10
Country: Number of subjects enrolled	France: 12
Country: Number of subjects enrolled	Germany: 13
Country: Number of subjects enrolled	Italy: 33
Country: Number of subjects enrolled	Brazil: 29
Country: Number of subjects enrolled	United States: 53
Country: Number of subjects enrolled	Canada: 5
Country: Number of subjects enrolled	South Africa: 18
Worldwide total number of subjects	194
EEA total number of subjects	80

Notes:

Subjects enrolled per age group

In utero	0
----------	---

Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	7
Adults (18-64 years)	186
From 65 to 84 years	1
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Subjects who met all of the inclusion criteria and none of the exclusions criteria at Screening were included in the study

Pre-assignment period milestones

Number of subjects started	194
Number of subjects completed	194

Period 1

Period 1 title	Baseline (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Treated
------------------	---------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Emixustat hydrochloride
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

10 mg QD

Arm title	Placebo
------------------	---------

Arm description: -

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

QD

Number of subjects in period 1	Treated	Placebo
Started	128	66
Completed	127	66
Not completed	1	0
Protocol deviation	1	-

Baseline characteristics

Reporting groups

Reporting group title	Treated
-----------------------	---------

Reporting group description: -

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Reporting group values	Treated	Placebo	Total
Number of subjects	128	66	194
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	5	2	7
Adults (18-64 years)	122	64	186
From 65-84 years	1	0	1
85 years and over	0	0	0
Gender categorical			
Units: Subjects			
Female	59	29	88
Male	69	37	106

End points

End points reporting groups

Reporting group title	Treated
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	

Primary: Primary Efficacy Endpoint

End point title	Primary Efficacy Endpoint
End point description:	
End point type	Primary
End point timeframe:	24M

End point values	Treated	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	128	66		
Units: mm ² per year				
number (not applicable)	1.280	1.309		

Statistical analyses

Statistical analysis title	Slope estimate
Comparison groups	Treated v Placebo
Number of subjects included in analysis	194
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8091
Method	slope estimate

Adverse events

Adverse events information

Timeframe for reporting adverse events:

24M

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.0
--------------------	------

Reporting groups

Reporting group title	Safety Analysis Set
-----------------------	---------------------

Reporting group description: -

Serious adverse events	Safety Analysis Set		
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 193 (1.04%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Cardiac disorders			
angina pectoris			
subjects affected / exposed	2 / 193 (1.04%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	Safety Analysis Set		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 193 (0.52%)		
Eye disorders			
Visual acuity reduction			
subjects affected / exposed	1 / 193 (0.52%)		
occurrences (all)	1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported